A drug company’s request is prompting Health Canada to consider approving higher non-prescription sales of the painkiller ibuprofen. The department declined an interview, and would not disclose research it claimed justified the regulatory change: “A manufacturer has submitted acceptable information”.
This content is for Blacklock’s Reporter members only. Please login to view this content. (Register here.)
